HAWTHORNE, N.Y.–(BUSINESS WIRE)–Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and year ended March 31, 2022. Quarter ended March 31, 2022 Highlights ─ compared to March 31, 2021 The quarter ended March 31, 2022, includes one month’s results from the February 28th acquisition of Alchemee. … [Read more…]
– ALPN-303 Novel Preclinical Data and Preliminary Phase 1 Data at EULAR – – Davoceticept (ALPN-202) Monotherapy Update and Trials in Progress Poster for Pembrolizumab Combination Study at ASCO – SEATTLE–(BUSINESS WIRE)–Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today … [Read more…]
– Study to assess safety of MRx0518 with BAVENCIO and effect on progression-free survival at 6 months – Study sites are open for patient enrolment LEEDS, England–(BUSINESS WIRE)–4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today … [Read more…]
NEW YORK–(BUSINESS WIRE)–Flatiron Health today announced three Flatiron-authored abstracts have been accepted for poster discussion and presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 3-7. “As demonstrated by our research at ASCO this year, we are at the forefront of our industry to improve patient lives through … [Read more…]
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the publication of preclinical data on AU-011, its first VDC product candidate, in combination with immune checkpoint inhibitors. AU-011 is being developed for the treatment of life-threatening cancers … [Read more…]
– Randomized Phase 3 Clinical Trial of ADCETRIS Combination Met Key Secondary OS Endpoint, Demonstrating a 41% Reduction in Risk of Death vs. Standard of Care in Patients With Advanced Hodgkin Lymphoma – CAMBRIDGE, Mass. & OSAKA, Japan & BOTHELL, Wash.–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502) and Seagen Inc., (NASDAQ:SGEN) today announced that overall survival … [Read more…]
– Results demonstrated an objective response rate of 54% and an overall clinical benefit rate of 91% – ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) today announced results from a phase 2, investigator-sponsored trial of cabozantinib (CABOMETYX®) in combination with pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The data … [Read more…]
First disclosure of results from primary analysis of Phase 2 PILOT study shows Breyanzi delivered complete responses in more than half of patients with refractory or relapsed large B-cell lymphoma after first-line therapy who were not deemed candidates for stem cell transplant PILOT patient-reported outcomes analysis showed treatment with Breyanzi improved health-related quality of life … [Read more…]
SAN DIEGO & TOKYO–(BUSINESS WIRE)–MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced that an abstract highlighting data and information from the Phase 2 … [Read more…]
Multiple epcoritamab (DuoBody®-CD3xCD20) poster presentations highlighting data in a variety of treatment settings and hematologic malignancies Oral presentation of tisotumab vedotin first-line combination study in patients with recurrent or metastatic cervical cancer Several abstracts evaluating Genmab owned and partnered programs accepted for presentation COPENHAGEN–(BUSINESS WIRE)–Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating several … [Read more…]
